Overview
Prostate cancer is one of the most prevalent cancers among men, and high-quality real-world data is crucial for understanding comparative effectiveness, unmet needs, and safety. However, existing sources often lack clinical detail on biomarkers, oral therapies, and progression. This study introduces a comprehensive dataset from the UK Flatiron Health Research Database, which includes data provided by patients and collected by the National Health Service as part of their care and support for prostate cancer.
By analyzing data from 2,263 patients diagnosed between 2011 and 2024, the study provides insights into patient demographics, clinical characteristics, biomarker testing, treatment regimens, and mortality. The dataset includes a high level of detail and completeness, including prostate cancer-specific variables with 97% and 93% of patients having documented Gleason score and PSA at diagnosis, respectively.
Why this matters
This dataset fills critical gaps in existing prostate cancer data by offering a detailed view of real-world treatment and outcomes in the UK. The ability to harmonize this dataset with international counterparts from the US, UK, and Japan allows for a global perspective on prostate cancer management. Such comprehensive data supports the development of personalized treatment strategies and highlights areas for improvement in clinical practice and paves the way for more effective interventions worldwide.